Japan and China dominate Asian API market
The market for active pharmaceutical ingredients (APIs) is highest in the USA, followed by Europe and Asia Pacific – the geographic market reporting fastest growth. According to a new report on companiesandmarkets.com, revenue growth in the Asia-Pacific API market is likely to increase at a rate of 9.6% a year between 2010 and 2016, following a rate of 6.7% between 2005 and 2010.
Manufacturing of active pharmaceutical ingredients is moving from established Western markets to more emerging regions, particularly India and China. Fluctuating prices of raw materials in these countries is a cause for concern for many API production companies, as when material costs are high, profit margins are eroded – a factor which could influence growth in the Asia-Pacific API market.
Generic APIs made up 71.5% of sector
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze